Compare NAII & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAII | NOTV |
|---|---|---|
| Founded | 1980 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 23.0M |
| IPO Year | 1987 | 1997 |
| Metric | NAII | NOTV |
|---|---|---|
| Price | $3.20 | $0.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 16.2K | ★ 418.8K |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $134,440,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.00 | 4.54 |
| 52 Week Low | $2.57 | $0.60 |
| 52 Week High | $4.40 | $5.67 |
| Indicator | NAII | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 29.66 |
| Support Level | $3.14 | $0.61 |
| Resistance Level | $3.46 | $0.69 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 72.52 | 2.55 |
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.